Analysis of 2014-2020 US Medicare claims matched empagliflozin initiators aged 65 and over with type 2 diabetes against DPP-4 inhibitor and GLP-1 initiators. Against DPP-4 inhibitors, the hazard ratio was 0.72 for admission with heart failure and 0.66 for death from any cause. Absolute benefit was larger in those with existing cardiovascular disease, and similar across sex, race and socioeconomic measures.
Why it is interesting: Absolute benefit sits with those who already have cardiovascular disease, not with any particular social group.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.